Mark Cuban

Business

Apple Reportedly Shifts 2026 iPhone Strategy: Premium Models Take Priority, Standard Edition Faces Delay

Apple is reportedly planning to prioritize the launch of its three highest-tier iPhone models in 2026, while delaying the rollout of a new standard edition, according to a Nikkei Asia report citing sources familiar with the matter. The move signals a strategic pivot towards the premium segment amid ongoing supply chain considerations.

Jan 30, 2026

Business

CHAPTERS Group's Meteoric Rise: A 923% Return Over Five Years Weathers Recent Dip

Despite a recent 4.9% weekly pullback, shareholders of German-listed CHAPTERS Group (ETR:CHG) have seen staggering total returns exceeding 900% since 2019, fueled by explosive revenue growth. The journey highlights the potential rewards—and risks—of investing in high-growth, pre-profit companies.

Jan 30, 2026

Business

Capital Metals Eyes Profitability by 2028 as Analysts Forecast Aggressive Turnaround

London-listed mineral sands explorer Capital Metals (LON: CMET) is projected to reach breakeven within two years, with analysts forecasting a first profit in 2028. The debt-free company's path hinges on achieving a steep annual growth rate amid its investment phase in UK and Sri Lankan projects.

Jan 30, 2026

Business

Motorpoint Group's Declining Returns on Capital Raise Concerns Among Investors

Motorpoint Group, the UK's largest independent car retailer, is showing signs of strain as its return on capital employed (ROCE) has fallen significantly over the past five years. While still above the industry average, the downward trend, coupled with rising current liabilities, suggests challenges ahead for the London-listed firm.

Jan 30, 2026

Business

Analysts Flag LSL Property Services as Undervalued, Shares Trading at a Steep Discount

A new financial analysis suggests shares of UK property services group LSL could be trading at a significant discount to their estimated intrinsic value, presenting a potential opportunity for investors.

Jan 30, 2026

Business

Norfolk Southern Navigates Soft Demand, Touts Safety Gains and Cost Discipline in Q4

Despite a weaker-than-expected volume environment, Norfolk Southern reported in-line cost performance for Q4 and highlighted significant strides in operational safety and efficiency. Executives pointed to a pivotal year of structural change while outlining cost and capital expenditure guidance for 2026.

Jan 30, 2026

Business

Murphy Oil Navigates Price Volatility, Bets Big on Vietnam and Offshore Growth in 2026

Despite a challenging price environment, Murphy Oil (MUR) reported strong operational execution for 2025 and laid out a capital plan focused on funding key international and offshore projects. While near-term production is set to dip, CEO Eric Hambly highlighted a transformative discovery in Vietnam and strategic portfolio expansion as pillars for future growth.

Jan 30, 2026

Business

National Fuel Gas Kicks Off Fiscal 2026 with Strong Upstream Performance, Eyes Pipeline Growth and Ohio Acquisition

National Fuel Gas (NFG) reported robust first-quarter earnings, driven by a 29% surge in upstream EBITDA. Executives highlighted progress on pipeline expansions, strategic hedging against volatile gas prices, and the planned acquisition of CenterPoint's Ohio utility, while reaffirming full-year guidance.

Jan 30, 2026

Business

Karman Holdings (KRMN) Soars on Analyst Optimism: A Defense Tech Darling in the Making?

Karman Holdings (NYSE: KRMN) is capturing Wall Street's attention as a series of bullish analyst calls, including a significant price target hike from KeyBanc, fuel its ascent. The stock's rally is tied to sustained momentum in the aerospace and defense sector, though some advise caution after its rapid gains.

Jan 30, 2026

Business

Vera Therapeutics Sees Major Price Target Hikes as Analysts Bet Big on Its Kidney Disease Drug

Vera Therapeutics (VERA) is drawing bullish attention from Wall Street, with multiple analysts significantly raising price targets following a key competitor's FDA approval and revised revenue forecasts for its lead drug candidate.

Jan 30, 2026

Business

CS Disco (LAW) Gains Analyst Backing Amid AI-Driven Growth, But Is It a Buy?

Jefferies raises price target on CS Disco following strong Q3 results fueled by its Cecilia AI platform, yet maintains a cautious 'Hold' rating as the company balances growth investments against profitability.

Jan 30, 2026

Business

Bank of America Lifts Target on Xencor Amid Broader Biotech Sector Optimism

Bank of America has raised its price target for clinical-stage biopharma firm Xencor (XNCR), highlighting a cautiously improving landscape for the sector driven by data catalysts, M&A, and capital access.

Jan 30, 2026

Business

Analyst Cuts Pagaya Target But Stays Bullish Amid Strong Growth Metrics

Keefe Bruyette trimmed its price target on Pagaya Technologies (PGY) to $35, while maintaining an Outperform rating. The adjustment comes despite the AI-driven lending platform reporting robust Q3 growth and a record partner pipeline.

Jan 30, 2026

Business

Nuvation Bio's Ibtrozi Gains Favor on Strong Launch, Truist Raises Target

Truist Securities has increased its price target for Nuvation Bio, highlighting the promising early commercial traction of its oncology drug Ibtrozi, which is outpacing competitors in the ROS1 inhibitor space.

Jan 30, 2026

Business

Analysts Trim Targets on Duolingo Amid Questions Over User Growth Sustainability

DA Davidson joins Morgan Stanley in lowering price targets for language-learning app Duolingo, citing data suggesting daily active user growth may fall short of expectations despite a strong start to the year.

Jan 30, 2026

Business

Analysts Bullish on Riot Platforms After Strategic AMD Data Center Deal

Keefe Bruyette & Woods raises its price target on Riot Platforms (RIOT) to $23, citing a new long-term agreement with AMD that provides revenue visibility and supports the company's high-performance computing strategy.

Jan 30, 2026

Business

UBS Bets Big on Biotech Turnaround, Initiates Arcellx Coverage with $100 Target

UBS has launched coverage of Arcellx with a Buy rating and a $100 price target, signaling growing Wall Street confidence in a biotech sector recovery and spotlighting the company's promising CAR-T therapy for multiple myeloma.

Jan 30, 2026

Business

TD Cowen Stands By Alphatec (ATEC) With Buy Rating, Sees $20 Target Amid Coverage Shift

Despite a lowered price target following an analyst transition, TD Cowen maintains a bullish stance on Alphatec Holdings, citing undervalued growth drivers including a new regenerative bone graft partnership and a robust long-term revenue outlook.

Jan 30, 2026

Business

Analysts Bullish on Cipher Mining as Pivot to AI Infrastructure Gains Momentum

Keefe Bruyette significantly raises its price target for Cipher Mining (CIFR), citing the company's strategic expansion into AI and high-performance computing data centers as a key growth driver.

Jan 30, 2026

Business

Bank of America Bullish on Apellis, Upgrades to 'Buy' on Strong Drug Launch and Kidney Disease Prospects

Bank of America has upgraded Apellis Pharmaceuticals (APLS) to 'Buy,' citing robust early adoption of its drug Empaveli and significant undervaluation of its potential in treating rare kidney diseases, despite a more cautious outlook from Wells Fargo.

Jan 30, 2026